g-Nostics

g-Nostics was a biotechnology company focused on personalized medicine and pharmacogenetics, particularly in the field of smoking cessation. Its primary offering, NicoTest, was a genetic testing service that analyzed DNA to predict a smoker's likelihood of success with various cessation aids, such as nicotine replacement therapy or bupropion. The company aimed to optimize treatment strategies by matching patients with the most appropriate interventions based on their genetic predisposition to nicotine metabolism and addiction. By identifying specific variants in genes like CYP2A6, the service provided tailored advice to help individuals quit smoking more effectively. Although the company is no longer active, its legacy remains as an early example of applying genomic data to behavioral health and addiction treatment.